NasdaqHealth CarePharmaceutical PreparationsSOUTH SAN FRANCISCO, CA

BridgeBio Oncology Therapeutics, Inc. BBOT

Ask your AI

Estimated market cap $171.74M80.25M shares, shares as of Nov 5, 2026CIK 1869105

Insider trades, 12 mo

—

No open-market trades

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

23.2% of shares · 12 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in BridgeBio Oncology Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 10, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in BridgeBio Oncology Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No recent insider purchases or sales for this company.

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

18.60M shares

41 funds report BBOT. Values checked against market prices.

Funds own 74% of shares (Q2 2026)

66 funds hold the stock.

Q3 2026: 23% · 5,560 of ~8,900 funds reported so far

Q3 202571%
Q4 202573%
Q1 202672%
Q2 202674%
Q3 2026 (so far)23%

Q3 2026. 14 new, 12 added to, 10 trimmed, 39 exited since Q2 2026.

Top 13F holders
#
1	BlackRock, Inc. 13F ↗	4.01M	$16.4M	+86.2%
2	Alphabet Inc. 13F ↗	2.82M	$11.6M	unchanged
3	Regents of the University of California 13F ↗	2.51M	$10.3M	New
4	Laurion Capital Management LP 13F ↗	2.00M	$8.2M	unchanged
5	Vanguard Capital Management LLC 13F ↗	1.99M	$8.2M	-0.7%
6	Aisling Capital Management LP 13F ↗	1.02M	$4.1M	unchanged
7	State Street Corp 13F ↗	893,262	$3.7M	-13.8%
8	Geode Capital Management, LLC 13F ↗	556,989	$2.3M	-10.5%
9	Marshall Wace, LLP 13F ↗	482,935	$2.0M	New
10	BNP Paribas Financial Markets 13F ↗	349,576	$1.4M	+82.9%

Download CSV Every fund that holds BBOT, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What BridgeBio Oncology Therapeutics, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What BridgeBio Oncology Therapeutics, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q3 2025	42	—	56.81M	$657.5M
Q4 2025	53	+11	58.31M	$756.1M
Q1 2026	67	+14	57.48M	$514.2M
Q2 2026	66	-1	59.13M	$450.6M
Q3 2026	41	-25	18.60M	$76.2M

Each point is a quarter-end, from Q3 2025 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (107924102). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q3 2025) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes2 in 12 mo 8-K events3 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesForm 144 · 1 in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record IPO history2 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: BridgeBio Oncology Therapeutics, Inc.
Address: 256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO, CA 94080
Phone: 857 702 0377
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company, emerging growth company
Incorporated in: DE
Listed as: BBOT (Nasdaq)
Former names: Helix Acquisition Corp. II (until 2025)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$2.14−$0.21 (−8.94%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $2.04 · High $2.95Nov 13, 2026

Aug 13, 2026Low $2.04 · High $9.60Nov 13, 2026

Nov 13, 2025Low $2.04 · High $13.73Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.